✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Comparison

Ozempic vs Rybelsus

Released: Last reviewed:

Ozempic vs Rybelsus: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.

Side-by-sideTrial-cited
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Comparison: Ozempic vs Rybelsus

Both are reviewed at American Telehealth Review against published clinical evidence and FDA labeling.

Key differentiators

Other comparisons

All comparisons →

Key facts, checked November 20, 2026

Ozempic is a weekly semaglutide injection; Rybelsus is daily oral semaglutide. Both are approved for type 2 diabetes: the Ozempic injection label and the Rybelsus and Ozempic tablets label each cover blood-sugar control and cardiovascular risk reduction in eligible adults. FDA’s shortage data mark the original Rybelsus 3, 7 and 14 mg tablets as “to be discontinued” (June 4, 2026). The CMS fact sheet on 2027 negotiated prices lists one $274 Medicare price for a 30-day supply of Ozempic, Rybelsus or Wegovy from January 1, 2027.